You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Bioimpedance based Intracranial Mapping for Monitoring Evolving TBI

    SBC: RYTEK MEDICAL INC            Topic: 105

    ABSTRACT Approximately million individuals suffer from traumatic brain injury TBI annually with over expected to die as a result of their injury In these most severe cases patients are typically admitted to the intensive care unit ICU for continuous monitoring and treatment of their injury Standard monitoring includes implantation of an intracranial pressure ICP sensor arterial ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Design and Development of Immunotolerant S. aureus Biotherapies

    SBC: Lyticon LLC            Topic: R

    The increasing incidence of multi drug resistance in Staphylococcus aureus and other bacteria represents a public health crisisTwo thirds of hospital associated Saureus infections andof those acquired in the community are now methicillin resistantMRSAMRSA causes rtinfections in the US each yearand it is responsible for half of all US deaths caused by drug resistant bacteriaThis threat to public he ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. DEVELOPMENT OF A NOVEL ANTIVIRAL TO TREAT AND PREVENT ACYCLOVIR RESISTANCE IN HUMAN OCULAR HERPES KERATITIS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: N

    ABSTRACT Infection of the eye by Herpes Simplex Virus HSV can result in Herpes Keratitis HK which is the leading cause of corneal blindness worldwide In the U S nearly individuals experience ocular herpes infections that are often recurrent and culminate in progressive corneal scarring and loss of vision The gold standard of care for HK is treatment with Acyclovir ACV that t ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Tools for site specific antibody immobilization for immunoassays

    SBC: ALPHATHERA            Topic: N

    Antibodies most commonly Immunoglobulin Gs IgGs are widely used in research and diagnostic assays due to their wide array of targets high specificity and proven efficacy In many of these immunoassays e g ELISAandapos s biosensors etc antibodies must be immobilized onto surfaces The sensitivity stability and longevity of antibodies used in this context are highly dependent on orien ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    Polo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. eHealth Mobile Technology Connecting Young Adults to Routine Engagement eMCARE a theoretically and empirically driven mobile intervention to engage young adults in healthcare

    SBC: NURELM, INC.            Topic: NICHD

    eMCARE EHealth Mobile Technology Connecting Young Adults to Routine Engagement Young adults YAs ages have a worse health profile than adolescents or adults in their late twenties and thirties Most YAs in the US experience no preparation for the transition from pediatric to adult care often seeking care only through emergency department ED visits The results can be seen across issues ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Inhibitors of Hydrogen Sulfide Metabolism as a Novel Treatment for Heart Failure

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NHLBI

    The goal of this Phase I STTR grant application is to capitalize on our recent discovery of novel sulfide quinone oxidoreductase SQOR inhibitors by the design and preparation of new analogs for the treatment of heart failure that enable us to understand SAR so as to improve potency and optimize ADME PK properties Heart failure is a highly lethal disease affecting more than million adults in t ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Scaffold to Promote Skin Regeneration

    SBC: FirstString Research, Inc            Topic: NIAMS

    PROJECT SUMMARY Dermal scarring affects more than million people worldwide annually over million people are injured in motor vehicle accidents over million patients are severely burned and thousands of warriors are wounded in military blasts In severe burns more than of patients develop hypertrophic scar contraction which leads to hypertrophic scar contractures HSc HSc a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Inhibitors of PSMB and PSMB for the Treatment of Multiple Myeloma

    SBC: InhiProt            Topic: 103

    Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Preparation of site specific antibody drug conjugates by proximity based sortase ligation

    SBC: ALPHATHERA            Topic: 103

    There has been growing interest in the use of antibody drug conjugates ADCs for the treatment of cancer as mounting data suggests an increase in anti tumor effectiveness and reduced toxicity compared with the administration of unlabeled antibodies in combination with chemotherapy The two ADCs that are currently approved by the FDA brentuximab vedotin Adcetris and ado trastuzumab emtansin ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government